摘要
目前最为有效的乳腺癌治疗模式是多学科综合标准化治疗。然而长期以来缺乏有效的预后预测手段来指导患者的个体化治疗,以至于相当一部分化疗获益甚少的低风险患者也不得不接受化疗。随着基因组学的发展,已有数个基因系列的检测结果被证实可以用于乳腺癌预后的预测,进而判断测患者从化疗中的获益,避免过度治疗。21基因Oncotype Dx检测正是其中之一,其有效性及准确性已在各种临床研究中得到了证实。本文就21基因Oncotype Dx对乳腺癌预后研究的进展进行综述。
Currently the most effective treatment strategy for breast cancer is standardized multi-discipline comprehensive treatment. However, there are no effective models that can accurately predict prognosis, so that no guidance of individualized treatment has yet been set up, resulting in a proportion of patients with low risk who received chemotherapy with little benefit. With the development of genomics, several gene sets have been demonstrated to be helpful in predicting of breast cancer prognosis and grading the patients＇ benefit from chemotherapy, thus avoid overtreatment. 21-gene Oncotype Dx was reported as one of them and has been demonstrated to be effective and accurate in various clinical studies. This paper summarizes researches on 21-gene Oncotype Dx in breast cancer.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2009年第12期953-958,共6页
China Oncology
